Delving into the Latest Updates on BW-20507 with Synapse

Overview

Drug Type

siRNA

Synonyms

HBV(Shanghai Argo Biopharma), BW-03, BW-20507

Target

Action

inhibitors

Mechanism

HBV RNA inhibitors(HBV RNA inhibitors)

Therapeutic Areas

Active Indication

Inactive Indication-

Originator Organization

Active Organization

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

RegulationBreakthrough Therapy (China)

Login to view timeline

Boost your research with our RNA technology data.

login

or

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis B, Chronic	Phase 2	Australia	ARGO BIOPHARMA AUSTRALIA PTY LTD	03 Jul 2023
Hepatitis B, Chronic	Phase 2	Hong Kong	ARGO BIOPHARMA AUSTRALIA PTY LTD	03 Jul 2023
Hepatitis B, Chronic	Phase 2	Thailand	ARGO BIOPHARMA AUSTRALIA PTY LTD	03 Jul 2023

Login to view more data

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Company_Website Manual	Phase 1/2	Hepatitis B, Chronic	-	BW-20507	wgtndlqlox(qhgqlkouaq) = BW-20507 administered subcutaneously every four weeks for a total of three doses demonstrated significant, dose-dependent reductions in HBsAg, with maximum declines of -2.9 to -3.2 log₁₀ IU/mL observed in the 200 mg and 400 mg cohorts. ptaognuvjw (ssswxrltqy ) View more	Positive	07 May 2025